ClinicalTrials.gg
RecruitingNCT07142291Updated Jul 23, 2026

PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS

A Phase 2 interventional study of Cromolyn Sodium (34.2 mg BID) and Cromolyn Sodium (17.1 mg BID) in Amyotrophic Lateral Sclerosis (ALS), sponsored by PhenoNet, Inc.. Recruiting at 22 sites in 6 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by PhenoNet, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain — 11 open to participants now, 16 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Spain.

Planned enrollment
30th of 51
105 · median 227
Started
2025
with 3 others
Phase 2
13 of 56
2 open now
Primary completion
2027-03
later than 7 of 15 live
Registered
50th of 56
by date

Among the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, this one is the 30th largest by planned enrollment of the 51 interventional ones that give a count, is one of 4 that started in 2025, is one of 13 in phase 2, reaches primary completion later than 7 of the 15 other live ones, and was the 50th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

11 of the 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 56 studies in Amyotrophic Lateral Sclerosis with a site in Spain, or all of them as a file.
02

Study summary

The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonary function tests (PFTs), such as forced vital capacity (FVC), and measuring neuro-inflammatory biomarkers in the blood.

Read the detailed description

This is a Phase IIB, randomized, double-blind, placebo-controlled study designed to assess the effects of PHENOGENE-1A (oral inhalation via dry powder inhaler [DPI]) in subjects with mild to moderate ALS disease. Eligible subjects will be randomized to receive either low dose PHENOGENE-1A (34.2 mg per day: in 2 doses of 17.1 mg and matching placebo BID), high dose PHENOGENE-1A (68.4 mg per day: 34.2 mg BID), or placebo (2 matching placebo capsules BID) (see table below), in a 2:2:1 ratio. Subjects will receive treatment for a duration of 24 weeks. All subjects must be on a stable dose of Riluzole 50 mg BID (100 mg daily) for at least 4 weeks prior to randomization and must continue their Riluzole regimen, 50 mg BID (100 mg daily), as standard-of-care treatment, throughout the 24 week treatment period.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Amyotrophic Lateral Sclerosis
  • Lou Gehrigs Disease
  • ALS
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosis of ALS; the diagnosis of ALS defined by revised El Escorial criteria as follows:

    1. Evidence of lower motor neuron (LMN) degeneration by clinical, electrophysiological, or neuropathological examination.
    2. Evidence of upper motor neuron (UMN) degeneration by clinical examination.
    3. Progressive spread of symptoms or signs within a region or to other regions, as determined by clinical examination or the history of disease progression.
    4. Absence of electrophysiological, neuroimaging, or pathological evidence of other diseases that might explain the UMN or LMN degeneration and exclusion of other causes.
  2. Male or female subjects aged 18 to 75 years inclusive.
  3. Must provide written for study-related procedures.
  4. Must be capable of completing all study-related procedures, assessments, and visits in the judgment of Investigator.
  5. Disease duration from ALS symptom onset of motor weakness ≤24 months.
  6. ALSFRS-R total score ≥38 at screening visit.
  7. ALSFRS-R Breathing subscore should be ≥9 at the time of screening.
  8. ALSFRS-R Bulbar subscore should be ≥9 at the time of screening.
  9. Forced vital capacity >70% of predicted value.
  10. PIFR ≥100 L/minute.
  11. Must be receiving a stable dose of standard-of-care treatment Riluzole for 4-weeks before signing informed consent.
  12. Female subjects who are of must agree to use of highly effective methods of consistent with local regulations during the study, and for 3 months after the study drug administration. Examples include the following, but not limited to:

    1. Combined (estrogen and progestogen containing) or progestogen-only hormonal contraceptives;
    2. Intrauterine device or intrauterine hormone-releasing system; OR
    3. status must have experienced their last menstrual period minimum of 1 year prior to study drug administration; OR
    4. Surgically sterilized. Female subject should be willing to not donate egg during the trial and for 3 months after the last dose of the study drug.
  13. Male subjects who are sexually active with a female of childbearing potential must agree to use highly effective contraception as described above, or a combination of 2 acceptable methods of contraception (e.g., a barrier method along with a female partner using a hormonal contraceptive method), in accordance with local regulations, throughout the duration of the study, and for 3 months after the last dose of the study drug.

(Male subject should be willing to not donate sperm during the trial and for 3 months after the last dose of the study drug.)

Exclusion criteria

Exclusion Criteria:

  1. ALSFRS-R score change (decrease) by 2.5 or more points between the screening visit and Day 1 (baseline) score.
  2. Bulbar onset ALS (\<9 bulbar subscore)
  3. Any use of non-invasive ventilation (e.g., continuous positive airway pressure, non-invasive bi-level positive airway pressure or non-invasive volume ventilation) for any portion of the day, or mechanical ventilation via tracheostomy, or on any form of oxygen supplementation.
  4. Any other significant neurological disorder which can interfere with study assessments, e.g., significant cognitive impairment and/or clinical dementia.
  5. Significant psychiatric illness like schizophrenia, bipolar disorder etc. Subjects with depression can be included, only if the depression has been stable and no episode of major depression has occurred in the past year.
  6. Severe cardiac disease (e.g., >500 ms), Torsade de Pointes, evidence of significant heart failure ( [NYHA] Class 3 or greater, myocardial infarction or unstable angina in the 6 months prior to screening).
  7. Any moderate-to-severe pulmonary disease or difficulty taking inhaled drugs.
  8. Inability to tolerate the administration of an oral inhaled powder via DPI.
  9. Has taken any product within 30 days or 5 half lives of the drug, whichever is longer, prior to dosing.
  10. Taking inhaled protein products on a chronic basis (such as insulin, parathyroid hormone, etc).
  11. Subjects with a body weight of 32 kg or less, or a of \<17.5 or >35.0 at time of screening.
  12. Moderate-to-severe liver disease: (AST), alanine aminotransferase (ALT) >3 times the ; total > 1.5 x ULN.; subjects with hepatic diseases such as hepatic cirrhosis, hepatic cancer and active hepatitis.
  13. Moderate-to-severe renal disease: \<45 mL/min/1.73 m2 (by Cockcroft-Gault calculation).
  14. Any disorder or laboratory abnormality that, in the Investigator's opinion, could interfere with the subject's participation in the study, place the subject at increased risk, or confound interpretation of the study results.
  15. Pregnant or breast-feeding females.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Low Dose PHENOGENE-1A (17.1 mg BID)

    17.1 mg, BID, oral inhalation via dry powder inhaler

    Drug: Cromolyn Sodium (17.1 mg BID) · Drug: Riluzole (100 mg)

  • Experimental
    High Dose PHENOGENE-1A (34.2 mg BID)

    34.2 mg, BID, oral inhalation via dry powder inhaler

    Drug: Cromolyn Sodium (34.2 mg BID) · Drug: Riluzole (100 mg)

  • Placebo comparator
    Placebo

    Placebo comparator matched to active treatment, BID, oral inhalation via dry powder inhaler

    Drug: Placebo · Drug: Riluzole (100 mg)

Interventions

  • 17.1 mg, BID, oral inhalation

    Also known as: Cromolyn, Sodium Cromoglycate

  • 34.2 mg, BID, oral inhalation via dry powder inhaler

    Also known as: Cromolyn, Sodium Cromoglycate, PHENOGENE-1A

  • DrugPlacebo

    Placebo comparator matched to active treatment.

  • 50 mg, oral tablet, BID, standard of care treatment

    Also known as: Rilutek

06

What researchers measure

Primary outcomes

  1. Absolute change in ALSFRS-R total score from baseline to Week 24

    To evaluate the effects of PHENOGENE-1A (cromolyn) on functional changes in subjects with mild to moderate ALS using the ALS Functional Rating Scale-Revised (ALSFRS-R).

    Time frame: Baseline to Week 24

  2. Incidence and severity of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)

    To evaluate the safety of PHENOGENE-1A following 24 weeks of twice daily (BID) treatment.

    Time frame: Baseline to Week 24

Secondary outcomes

  1. Mean rank for CAFS at Week 24

    To evaluate the effects of PHENOGENE-1A on function and survival using the Combined Assessment of Function and Survival (CAFS).

    Time frame: Baseline to Week 24

  2. Time to event requiring full-time or nearly full-time respiratory support

    Time from randomization to the first of 7 consecutive days on which permanent assisted ventilation (invasive or non-invasive) was used for \>22 hours/day due to ALS progression.

    Time frame: Randomization to Week 24

  3. Mean change in percent predicted forced vital capacity (%FVC) from baseline to Week 24

    To evaluate the effect of PHENOGENE-1A on respiratory changes.

    Time frame: Baseline to Week 24

  4. Mean change in peak inspiratory flow rate (PIFR) from baseline to Week 24

    To evaluate changes in PIFR (L/min) during treatment.

    Time frame: Baseline to Week 24

  5. Absolute Values and Changes From Baseline in Vital Signs From Baseline to Week 24 by Treatment Arm

    Vital signs will include: * Systolic blood pressure (mmHg) * Diastolic blood pressure (mmHg) * Pulse rate (beats per minute) * Respiratory rate (breaths per minute) * Body temperature (°C or °F, as recorded) Results will be summarized as: * Absolute values for each parameter at each scheduled visit. * Changes from baseline at each visit. * Summaries will be presented separately by treatment arm.

    Time frame: Baseline to Week 24

  6. Number and Percentage of Subjects With Abnormal Clinical Laboratory Values and Changes From Baseline to Week 24 by Treatment Arm

    Safety laboratory assessments will include hematology, clinical chemistry, coagulation, and urinalysis panels. Each laboratory result will be classified as normal, abnormal (not clinically significant), or abnormal (clinically significant). Results will be summarized as: Number and percentage of subjects with abnormal laboratory values at each post-baseline visit, by treatment arm. Summary statistics for absolute values and changes from baseline at each visit.

    Time frame: Baseline to Week 24

  7. Number and Percentage of Subjects With Abnormal Physical Examination Findings From Baseline to Week 24 by Treatment Arm

    The physical examination will assess head/neck, eyes, ears, nose/throat, cardiovascular, respiratory, abdominal, musculoskeletal, extremities, and skin systems. Each system will be classified as normal, abnormal (not clinically significant), or abnormal (clinically significant). Results will be summarized as the number and percentage of subjects with abnormal findings at each post-baseline visit.

    Time frame: Baseline to Week 24

  8. Number and Percentage of Subjects With Abnormal Neurological Examination Findings From Baseline to Week 24 by Treatment Arm

    The neurological examination will assess mental status, motor function, sensory function, reflexes, and coordination/cerebellar function. Each domain will be classified as normal, abnormal (not clinically significant), or abnormal (clinically significant). Results will be summarized as the number and percentage of subjects with abnormal findings at each post-baseline visit.

    Time frame: Baseline to Week 24

  9. Number and Percentage of Subjects With Abnormal Electrocardiogram (ECG) Findings From Baseline to Week 24 by Treatment Arm

    Standard 12-lead ECGs will be performed at protocol-specified visits. Parameters assessed will include: * Heart rate: 60-100 beats per minute (bpm) * PR interval: 120-200 milliseconds (ms) * QRS duration: 70-110 ms * QT interval: \< 440 ms in men, \< 460 ms in women * Corrected QT interval (QTcF, Fridericia's formula): \< 450 ms in men, \< 470 ms in women Each ECG result will be classified by the investigator as normal, abnormal (not clinically significant), or abnormal (clinically significant), using these ranges as reference. Results will be summarized as the number and percentage of subjects with abnormal ECG findings at each post-baseline visit.

    Time frame: Baseline to Week 24

  10. Number and Percentage of Subjects With Suicidal Ideation, Suicidal Behavior, or Self-Injurious Behavior Without Suicidal Intent on the Columbia Suicide Severity Rating Scale (C-SSRS) From Baseline to Week 24 by Treatment Arm

    The Columbia Suicide Severity Rating Scale (C-SSRS) will be administered at protocol-specified visits to assess suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent. * Suicidal ideation will be captured using categories 1-5 of the C-SSRS (ranging from passive wish to be dead to active suicidal ideation with plan and intent). * Suicidal behavior will be captured using categories 6-10 of the C-SSRS (preparatory acts, aborted attempts, interrupted attempts, and actual attempts). * Self-injurious behavior without suicidal intent will be reported separately. Results will be summarized as: Number and percentage of subjects with suicidal ideation, suicidal behavior, and self-injurious behavior without suicidal intent, compared between active treatment and placebo arms.

    Time frame: Baseline to Week 24

  11. Number and Percentage of Subjects Who Discontinue Study Participation Due to Adverse Events From Baseline to Week 24

    The incidence of study discontinuation attributed to treatment-emergent adverse events (TEAEs) will be assessed. Results will be summarized as the number and percentage of subjects who withdraw from the study due to an adverse event, presented separately by treatment arm.

    Time frame: Baseline to Week 24

Other outcomes

  1. Change in plasma neuroinflammatory biomarkers from baseline to Week 24

    To evaluate the impact of two different doses of PHENOGENE-1A on neuroinflammation.

    Time frame: Baseline (pre-dose) to Week 24

07

Study locations

22 of 22 sites recruiting
  • Honor Health Neurology - Bob Bove Neuroscience Institute
    Scottsdale, Arizona 85251, United States
    Recruiting
  • University of California San Diego
    La Jolla, California 92037, United States
    Recruiting
  • Sutter Health - California Pacific Medical Center Research Institute
    San Francisco, California 94115, United States
    Recruiting
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
    Recruiting
  • Lange Neurology
    New York, New York 10065, United States
    Recruiting
  • NEUROHK s.r.o.
    Hradec Králové, 50002, Czechia
    Recruiting
  • Fakultni Nemocnice Hradec Kralove
    Hradec Králové, 50005, Czechia
    Recruiting
  • Thomayer University Hospital - Fakultni Thomayerova nemocnice
    Prague, 14059, Czechia
    Recruiting
  • Charité Centrum für Neurologie, Neurochirurgie und Psychiatrie
    Berlin, 13353, Germany
    Recruiting
  • DIAKOVERE Henriettenstift - Klinik für Neurologie und Klinische Neurophysiologie
    Hanover, 30171, Germany
    Recruiting
  • Universitaetsklinikum Schleswig-Holstein
    Lübeck, 23538, Germany
    Recruiting
  • Michalski i Partnerzy Lekarze Spółka Partnerska
    Krakow, 31-426, Poland
    Recruiting
  • SP ZOZ Szpital Uniwersytecki w Krakowie
    Krakow, 51-503, Poland
    Recruiting
  • Centrum Medyczne NeuroProtect (NeuroProtect Medical Center)
    Warsaw, 01-684, Poland
    Recruiting
  • City Clinic Research
    Warsaw, 02-473, Poland
    Recruiting
  • University Clinical Center of Serbia
    Belgrade, 11000, Serbia
    Recruiting
  • Hospital General Universitario Dr. Balmis de Alicante
    Alicante, 3010, Spain
    Recruiting
  • Barcelona Sea Hospital (Hospital Del Mar De Barcelona)
    Barcelona, 8003, Spain
    Recruiting
  • Hospital Universitario Vall D Hebron
    Barcelona, 8035, Spain
    Recruiting
  • Hospital Universitario Ramon Y Cajal
    Madrid, 28034, Spain
    Recruiting
  • Hospital Regional Universitario De Malaga
    Málaga, 29010, Spain
    Recruiting
  • Hospital Universitario Virgen Del Rocio
    Seville, 41013, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.

Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's planned 16 months is below that.

Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Aug 26, 2025
StartActual
Nov 25, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07142291
Lead sponsor
PhenoNet, Inc.
Responsible party
Sponsor
First posted
Aug 26, 2025
Start date
Nov 25, 2025
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

David R Elmaleh, PhD
Contact
delmaleh@phenonet.us
+1 (617) 784-0490
Atul Gupta, M.D.
Contact
agupta@phenonet.us
+91-9717287654

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cromolyn

Start the discussion